Psychedelics Summit 2026 – Where Do We Really Stand?
Psychedelic medicine is moving through a complicated moment, with promising research, regulatory setbacks, new access models, and serious questions about safety, ethics, evidence, and implementation all unfolding at once.
Rather than reducing the conversation to whether psychedelics simply “work” or “do not work,” this three-day online gathering brings researchers, clinicians, policy leaders, advocates, and pioneers together to examine what the evidence shows, where policy is moving, and what happens when new models of access meet real-world conditions.
You will hear live conversations alongside a curated collection of Essential Conversations covering MDMA, psilocybin, ibogaine, LSD, 5-MeO-DMT, psychedelic-assisted therapy, neuroscience, traditional approaches, regulation, facilitator standards, affordability, ethics, and responsible access.
The goal is a clearer and more current understanding of a field that cannot be responsibly understood through headlines alone.
Why Attend This Psychedelic Summit in 2026
The psychedelic field is changing quickly enough that information from only a few years ago can leave important parts of the current picture out. Research continues, regulatory questions are evolving, and the practical realities of access, training, safety, ethics, affordability, and quality of care have become central to the conversation.
This Psychedelic Summit is built around the areas where greater context matters most. Nine live conversations bring you into current discussions about evidence, policy, regulation, psychedelic-assisted therapy, and what can be learned as different approaches move beyond controlled research environments.
You will also hear perspectives that do not fit neatly into a single narrative about psychedelic medicine. The purpose is to examine both promise and complexity so you can better understand what researchers, clinicians, advocates, and policy leaders are discussing now.
Who Should Attend This Psychedelic Global Summit
This Psychedelic Global Summit is designed for people who want a serious, current understanding of psychedelic research, therapy, policy, access, and implementation. You do not need to work professionally with psychedelics to benefit from the conversations.
The program may be particularly useful if your work touches mental health, healthcare, education, research, policy, coaching, or wellness, or if you simply want to understand the field with more depth than a headline or social-media summary can provide.
- Mental health professionals and therapists
- Physicians, nurses, and other healthcare practitioners
- Psychedelic therapists and facilitators
- Coaches and wellness professionals
- Researchers, academics, and students
- Policy and advocacy professionals
- People considering professional education in psychedelic-assisted therapy
- Informed members of the public following psychedelic research and access
What You’ll Learn at the Psychedelic Assisted Therapy Summit
The Psychedelic Assisted Therapy Summit explores what current research is revealing about different compounds, therapeutic contexts, safety considerations, patient selection, neuroscience, and the limits of what can responsibly be concluded from the evidence so far.
You will also examine the policy and regulatory questions surrounding psychedelic-assisted therapies, including MDMA, psilocybin, ibogaine, LSD, 5-MeO-DMT, emerging compounds, federal and state developments, and different approaches to legal access.
Just as importantly, the summit looks at implementation: what happens when promising research meets systems of care, facilitator training, affordability, ethics, commercialization, quality standards, cultural responsibility, and the needs of real people and communities.
- Where evidence around MDMA, psilocybin, ibogaine, LSD, 5-MeO-DMT, and emerging psychedelic therapies currently stands
- How researchers are thinking about safety, outcomes, mechanisms, patient selection, and therapeutic context
- What recent regulatory developments mean for the future of psychedelic drug development
- How federal and state policy questions intersect with research and access
- What Oregon and Colorado can teach the field about moving policy into practice
- Why different psychedelic medicines may require different therapeutic models
- How facilitator training and standards affect responsible implementation
- Why affordability, equity, ethics, and commercialization remain central questions
- What traditional and Indigenous perspectives can contribute to conversations about plant medicine
- How neuroscience is shaping evolving models of psychedelic action and expanded states
Research, Policy and Rollout: The Psychedelics 2026 Framework
The summit is organized around three connected questions rather than a single claim about where psychedelic medicine is headed. That structure makes it possible to separate scientific evidence from policy decisions and from the practical challenges that appear when access expands.
The Research
What is the science telling us now about psychedelic compounds, therapeutic models, safety, efficacy, mechanisms, patient selection, and context? These conversations look at both promising findings and areas where the evidence still requires care and rigor.
The Policy
What happens next with approval pathways, scheduling, legalization, decriminalization, and state-level frameworks? The summit examines how regulatory decisions and policy choices affect research, clinical development, and access.
The Rollout
What happens when psychedelic services move from legislation and research into real-world settings? The discussion turns to facilitator training, standards, ethics, affordability, equity, commercialization, integration, and quality of care.
Featured Speakers at This Psychedelic Assisted Global Therapy Summit
The Psychedelic Assisted Global Therapy Summit brings together more than 20 experts across research, clinical practice, policy, advocacy, neuroscience, traditional approaches, and psychedelic education.
The live program is complemented by Essential Conversations that add context from previous Heart Mind Institute psychedelic and expanded-states gatherings.
Matthew Johnson, PhD — The State of Psychedelic Research
Matthew Johnson is Senior Investigator in Psychedelics at Sheppard Pratt and a pioneering, highly published psychedelic researcher. His conversation focuses on where evidence is strongest, what scientists are learning, and which questions still need careful investigation.
Rick Doblin, PhD — MDMA, Regulation and What Comes Next
Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies, joins the summit for a conversation about the long MDMA research journey, the regulatory process, lessons from recent developments, and the questions facing the field next.
Angie Allbee — Oregon Psilocybin Services
Angie Allbee, Senior Advisor with Oregon Psilocybin Services, brings an implementation perspective to the discussion. Her session explores what can be learned as psychedelic policy becomes practice and regulated access is put into operation.
Scott Thompson, PhD — Colorado and Natural Medicine Implementation
Scott Thompson is a professor of psychiatry and neuroscientist at the University of Colorado School of Medicine whose work includes depression and psychedelic therapeutics. His conversation considers Colorado’s emerging natural-medicine framework and the broader lessons that implementation may offer.
Ismail Ali, JD — Psychedelic Policy and Access
Ismail Ali is a psychedelic policy leader, attorney, Co-Executive Director of MAPS, and co-founder of the Psychedelic Bar Association. His session explores how federal policy, state policy, advocacy, regulation, and access efforts increasingly intersect.
Tania de Jong and David Rabin, MD, PhD
Tania de Jong, co-founder of Mind Medicine Australia, contributes an international policy and advocacy perspective. David Rabin is a board-certified psychiatrist, neuroscientist, and Senior Research Scientist at IHMC whose work includes stress, trauma, and psychedelic-assisted therapy.
Essential Conversations
Additional conversations include Paul Stamets on fungi; Anja Loizaga-Velder, PhD, on traditional and Indigenous approaches to plant medicine; Bessel van der Kolk, MD, on trauma and the body; and Robin Carhart-Harris, PhD, on the neuroscience of expanded states and evolving models of psychedelic action.
Psychedelics 2026 Summit Schedule and Daily Themes
The main summit runs October 13–15, 2026, with three live interviews and Q&A sessions each day at 10:00 a.m., 12:00 noon, and 2:00 p.m. Eastern Time. That corresponds to 7:00 a.m., 9:00 a.m., and 11:00 a.m. Pacific Time.
Essential Conversations are available on demand alongside the live program, giving you another way to explore research, clinical context, traditional perspectives, neuroscience, trauma, and psychedelic education on your own schedule.
Preparation Session — October 12
- Live preparation and Q&A session at 11:00 a.m. Eastern Time and 8:00 a.m. Pacific Time
- A chance to get oriented, prepare for the three-day program, and bring practical questions about participating
Day 1 — October 13
- 9:00 a.m. Eastern Time: Live meditation practice with Fleet Maull, PhD
- 10:00 a.m. Eastern Time: Live session and Q&A with Matthew Johnson, PhD
- 12:00 noon Eastern Time: Live session and Q&A with Angie Allbee
- 2:00 p.m. Eastern Time: Live session and Q&A with Ismail Ali, JD
- Essential Conversations available on demand throughout the day
Day 2 — October 14
- 9:00 a.m. Eastern Time: Live meditation practice with Fleet Maull, PhD
- 10:00 a.m. Eastern Time: Live session and Q&A with Paul Austin
- 12:00 noon Eastern Time: Live session and Q&A with Rick Doblin, PhD
- 2:00 p.m. Eastern Time: Live session and Q&A with Carolina Correa
- Essential Conversations available on demand throughout the day
Day 3 — October 15
- Three live interviews and Q&A sessions continue at 10:00 a.m., 12:00 noon, and 2:00 p.m. Eastern Time
- Essential Conversations remain available on demand during the summit access window
- The final day continues the wider discussion of research, policy, regulation, access, and implementation
Dates, Access, Replays and Where to Watch
Psychedelics 2026: Where Do We Really Stand? runs online from October 13 through October 15, 2026. Each day, registered participants receive an email containing the link to that day’s sessions.
The free sessions for each day are available for 24 hours beginning at 7:00 a.m. Eastern Time, which is 4:00 a.m. Pacific Time. You can watch at your own pace within that daily access window rather than viewing every session at its original live time.
The summit videos can be watched on a phone or iPad using the same daily link sent by email. Sessions are not delivered through Zoom. English closed captions and auto-translated subtitles are available through YouTube settings for summit videos.
A bonus 48-hour encore is scheduled to begin October 24 at 7:00 a.m. Eastern Time. Optional Lifetime Access is also available separately, with purchased summit access delivered to the Heart Mind Institute online library on October 15.
- Check your email each day for the current session link
- Look in Spam and Promotions if an access message does not appear
- Use the daily link on your preferred compatible device
- Plan around the 24-hour free viewing window for each day’s sessions
- Use the CC control in the playback window when captions are helpful
How to Register for Psychedelics 2026
Click any Register Here For Free button on this page, enter your contact information, and check your email for access details.
How to Get the Most From the Three-Day Psychedelic Summit
With live interviews, Q&A sessions, and a substantial library of Essential Conversations, the easiest way to benefit from the summit is to decide which questions matter most to you before the first day begins.
You can then use the 24-hour access windows to build a viewing plan around your interests instead of treating every session as equally urgent.
Choose Your Main Question
Start with research, policy, or real-world rollout. That gives you a practical lens for choosing live sessions and deciding which Essential Conversations deserve your attention first.
Separate Evidence From Possibility
- Notice when speakers are discussing established findings versus emerging hypotheses
- Write down questions you want to investigate further rather than turning every idea into a conclusion
Keep Health Decisions Separate From Summit Learning
Use the event as an educational resource. Personal decisions about mental health treatment, medications, psychedelic substances, or medical care belong in conversations with appropriately qualified professionals.
Make the Daily Emails Easy to Find
Move the first summit email to your primary inbox, mark it as safe, and keep the thread easy to locate so the next day’s access window does not get lost in your inbox.
About Fleet Maull, Ron Siegel, Sunny Strasburg and Heart Mind Institute
Fleet Maull, PhD, is the summit’s host-speaker and the founder of Heart Mind Institute and Prison Mindfulness Institute. He is a dharma teacher, executive coach, social entrepreneur, and the author of Radical Responsibility and Dharma in Hell.
Ron Siegel, PsyD, serves as a co-host. He is a psychology professor at Harvard Medical School, clinician, educator, and the author of The Extraordinary Gift of Being Ordinary: Finding Happiness Right Where You Are.
Sunny Strasburg, LMFT, also serves as a co-host. She is a certified psychedelic psychotherapist trained in Internal Family Systems, an EMDR-certified trauma specialist, consultant, and writer.
Together, the hosts guide conversations with guest researchers, clinicians, policy experts, advocates, educators, and pioneers. Their role is distinct from the featured experts who join individual sessions to address specific areas of research, policy, therapy, culture, neuroscience, and implementation.
Free Gifts and Bonus Teachings for Psychedelics 2026
Free registration also includes a selected collection of bonus teachings from three voices working across psychedelic medicine, Indigenous wisdom, and expanded states.
Belinda Eriacho
Explore an Indigenous perspective on plant medicine, cultural responsibility, relationship, humility, and respectful engagement with traditions that have long histories beyond contemporary psychedelic medicine.
Rick Doblin, PhD
Go deeper into the decades-long effort to bring MDMA-assisted therapy into clinical research and the vision that helped shape the modern psychedelic movement.
Marie Mbouni, MD
Explore expanded states of consciousness, healing, and approaches that connect modern medicine with broader dimensions of human experience.
Frequently Asked Questions
Select any question below to reveal the answer.
When is Psychedelics 2026: Where Do We Really Stand?
Is the Psychedelics 2026 summit free?
How do I access the three-day summit sessions?
What time are the live interviews in Pacific Time?
Do I need Zoom to participate in the summit?
Can I watch the summit on my phone or iPad?
How long can I watch each day’s summit sessions?
Are closed captions available during the summit?
What is Lifetime Access?
Where is purchased Lifetime Access delivered?
Is there an encore after the three-day summit?
What are the Essential Conversations?
Who is this psychedelic summit for?
What topics are covered during Psychedelics 2026?
How is the summit organized around research, policy and rollout?
Who are some of the featured speakers?
Who hosts Psychedelics 2026?
What free registration gifts are included?
Does the summit include live Q&A sessions?
Is this summit medical, psychological, or legal advice?
How do I register for Psychedelics 2026?
The contents of this website/e-mail are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. This website does not provide medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
We are grateful to be of service and bring you these life-changing events free of charge. In order to do this, please note that whenever you click the links and purchase items, in most (not all) cases we will receive a referral commission. We may receive a listing fee for publishing this event.
Your support in purchasing through these links makes it possible for people in over 150 countries globally to attend these life-changing events for free. Thank you!
Register for Psychedelics 2026: Where Do We Really Stand? to receive daily access details for three days of live conversations, Q&A sessions, Essential Conversations, and complimentary registration gifts.
- Oct 13 2026
- 8:00 am - 6:00 pm
Local Time
- Timezone: America/New_York
- Date: Oct 13 2026
- Time: 11:00 am - 9:00 pm
More Info
- Worldwide
